In our study, up to 40/50 newly diagnosed AML patients were CD81-positive, accounting for 80%; this result was higher than the study results of Boyer et al. (69%) and Hussein et al. (17/30 patients) [12,13]. The gene discussed is CD81; the disease is acute myeloid leukemia.